Prospective trial of intraoperative mitomycin C in the treatment of primary pterygium.
AUTOR(ES)
Cano-Parra, J
RESUMO
AIMS--A prospective, randomised, double blind, placebo controlled study of intraoperative mitomycin C as adjunctive treatment of primary pterygium was conducted. METHODS--A total of 66 eyes of 54 patients with primary pterygium were treated with excision, with or without a single intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes) to evaluate the efficacy and toxicity of this adjunctive treatment. The mean follow up was 14.1 months (range 12-23 months). RESULTS--Of the 36 eyes that underwent simple excision, 14 (38.8%) exhibited recurrences whereas only one of 30 eyes (3.33%) treated with excision and intraoperative application of mitomycin C had recurrence (p = 0.0006). Neither serious ocular complications nor systemic toxicity were noted in the mitomycin C treated group. CONCLUSION--Intraoperative mitomycin C appears to be an effective and safe adjunctive treatment of primary pterygium.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=505131Documentos Relacionados
- Long term results of intraoperative mitomycin C in the treatment of recurrent pterygium.
- Results of treatment with topical mitomycin C 0.02% following excision of primary pterygium.
- PTERYGIUM. ITS NATURE AND A NEW LINE OF TREATMENT*
- Role of mitomycin C in pterygium surgery.
- Pseudoelastic nature of pterygium.
